Keyphrases
Functional Magnetic Resonance Imaging
100%
Cognitive Impairment
100%
Diabetes
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Adiposity
100%
Olfactory Dysfunction
100%
Clinical Neuroimaging
100%
Obese Subjects
66%
Non-obese
33%
Receptor Agonist
33%
Patients with Diabetes
33%
Olfactory Function
33%
A1 Receptor
33%
Obese Men
33%
Glucagon-like
33%
Olfaction
16%
Negative Association
16%
Fasting Insulin
16%
Brain Function
16%
Brain Activation
16%
Functional Connectivity
16%
Early Diagnosis
16%
Therapeutic Approaches
16%
Metabolic
16%
Control Subjects
16%
Episodic Memory
16%
Glycemic Control
16%
Olfactory Test
16%
Left Hippocampus
16%
Therapeutic Effect
16%
Right Anterior Insula
16%
Mediation Analysis
16%
Neuroimaging
16%
Brain Networks
16%
Assessment Score
16%
Diagnosis Approach
16%
Psychological Behavior
16%
General Cognition
16%
Metformin Monotherapy
16%
Montreal Cognitive Assessment (MoCA)
16%
Impaired Cognition
16%
Brain Alterations
16%
Behavior Network
16%
Olfactory Network
16%
Parahippocampus
16%
Olfactory Threshold
16%
Nursing and Health Professions
Non Insulin Dependent Diabetes Mellitus
100%
Obesity
100%
Cognitive Defect
100%
Functional Neuroimaging
100%
Monotherapy
25%
Early Diagnosis
25%
Neuroimaging
25%
Therapy Effect
25%
Metformin
25%
Processing Speed
25%
Pharmacology, Toxicology and Pharmaceutical Science
Obesity
100%
Cognitive Defect
100%
Monotherapy
25%
Therapeutic Effect
25%
Metformin
25%
Neuroscience
Glucagon-Like Peptide-1 Agonist
100%
Medicine and Dentistry
Montreal Cognitive Assessment
12%
Insula
12%